Search

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Highlights of Past EHA (HOPE) Cairo 2018

EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.

Read more

SWG Educational Activities

EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten

Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

Read more

Publications

Machado HE, Mitchell E, Øbro NF, Kübler K, Davies M, Leongamornlert D, Cull A, Maura F, Sanders MA, Cagan ATJ, McDonald C, Belmonte M, Shepherd MS, Vieira Braga FA, Osborne RJ, Mahbubani K, Martincorena I, Laurenti E, Green AR, Getz…

Read more

SWG Educational Activities

In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.

Read more

FP9 recommendations BioMed Alliance

With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research.

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more